Company Filing History:
2 out of 3,381 
1 out of 547 
Years Active: 2012-2013
Title: Gregory Collins: Innovator in Dopamine Receptor Ligands
Introduction
Gregory Collins is a notable inventor based in Medford, MA (US). He has made significant contributions to the field of pharmacology, particularly in the development of ligands for the dopamine 3 (D) receptor. With a total of 2 patents, his work has implications for the treatment of various diseases.
Latest Patents
Collins' latest patents focus on potent and selective ligands for the dopamine 3 (D) receptor. The first patent discloses ligands with a structural formula where R is either Calkyl or Ccycloalkyl, and may be substituted with one or two halogens or OCalkyl. The second patent also pertains to ligands for the D3 receptor, featuring a structural formula where X is C=O or SO, and R can be Calkyl, aryl, heteroaryl, or other specified structures. These ligands are designed for use in treating conditions where modulation of the D receptor is beneficial.
Career Highlights
Throughout his career, Gregory Collins has worked at prestigious institutions such as the University of Michigan and the University of Kansas Medical Center Research Institute. His research has focused on the development of innovative compounds that can effectively target the D3 receptor.
Collaborations
Collins has collaborated with esteemed colleagues, including Shaomeng Wang and Jianyong Chen, contributing to the advancement of research in his field.
Conclusion
Gregory Collins is a prominent inventor whose work on dopamine receptor ligands has the potential to impact medical treatments significantly. His innovative research continues to pave the way for advancements in pharmacology.